Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management
Need to balance benefits and risks of long-term hormone therapy in postmenopausal women
Vault Navigation
Need to balance benefits and risks of long-term hormone therapy in postmenopausal women
What are the effects of long-term (at least 1 year) hormone therapy (HT) in perimenopausal and postmenopausal women during and after cessation of treatment?
In relatively healthy postmenopausal women, using combined continuous HT for 1 year increased the risk of a heart attack from about 2/1000 to 3–7/1000, and increased the risk of venous thrombosis from about 2/1000 to 4–11/1000. With longer use, HT also increased the risk of stroke, breast cancer, gallbladder disease and death from lung cancer. Oestrogen-only HT increased the risk of venous thrombosis after 1–2 years' use: from 2/1000 to 2–10/1000. With longer use, it also increased the risk of stroke and gallbladder disease, but it reduced the risk of breast cancer (after 7 years' use) from 25/1000 to 15–25/1000. Among women over 65 years of age taking continuous combined HT, the incidence of dementia was increased. Risk of fracture was the only outcome for which results showed strong evidence of clinical benefit from HT (both types).
The main limitation in the quality of evidence was that only about 30% of women were 50–59 years old at baseline, which is the age at which women are most likely to consider HT for vasomotor symptoms. Data were insufficient for the assessment of the risks of long-term HT in perimenopausal women or postmenopausal women younger than 50 years old.
HT is widely provided for control of menopausal symptoms and has been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women.
Marjoribanks J et al. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Reviews, 2017, Issue 1. Art. No.: CD004143.DOI: 10.1002/14651858. CD004143.pub5. This review contains 22 studies involving 43,637 participants.